Ticker LaunchIPO · TRDA
Entrada Therapeutics, Inc.
Formerly CycloPorters, Inc.
Entrada Therapeutics, Inc. (TRDA) priced its initial public offering on Nov 1, 2021 at $20.00 per share, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $597.7M. Goldman Sachs was lead-left underwriter, joined by TD Cowen and Evercore ISI. Goodwin Procter advised the company and Ropes & Gray advised the underwriters.
Entrada Therapeutics, Inc. develops Endosomal Escape Vehicle (EEV) therapeutics, small cyclic peptides conjugated to biological therapeutics. They are designed to reach intracellular targets long considered inaccessible, and the company is building a development portfolio on its EEV platform.
- Status
- IPO
- Ticker
- TRDA
- Exchange
- Nasdaq Global Market
- Priced
- Nov 1, 2021
- IPO price
- $20.00
- Market cap at IPO price
- $597.7M
- First filed
- Oct 8, 2021
- Underwriters
- Goldman Sachs, TD Cowen and Evercore ISI
- Company counsel
- Goodwin Procter
- Underwriters' counsel
- Ropes & Gray
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Oct 8, 2021
- Latest amendment Oct 25, 2021
- Final prospectus (424B4) Nov 1, 2021
- All filings on EDGAR CIK 1689375
Other Biotech & pharma IPOs in 2021
- IO Biotech, Inc.IOBT · Nov 8, 2021 · $100.1M
- LianBioLIAN · Nov 2, 2021 · $325M
- Biofrontera Inc.BFRI · Nov 1, 2021 · $18M
- Aura Biosciences, Inc.AURA · Nov 1, 2021 · $75.6M
- Xilio Therapeutics, Inc.XLO · Oct 22, 2021 · $117.6M
- Ventyx Biosciences, Inc.VTYX · Oct 21, 2021 · $151.6M